Literature DB >> 33437752

Don't forget about syphilis: sexually transmitted diseases during COVID-19 pandemic.

Andrea Di Buduo1, Laura Atzori1, Luca Pilloni2, Stefania Perla1, Franco Rongioletti1, Caterina Ferreli1.   

Abstract

A great heterogeneity of skin manifestations has been increasingly associated with SARS-CoV2 infection, and especially exanthematous eruptions are considered among early presenting signs in symptomatic patients. In this report, a 58-year-old patient presented with fever, generalized rash and systemic symptoms as urgent consultation to the Dermatology Clinic of Cagliari amidst the Italian outbreak in late March 2020. After a negative nasopharyngeal swab for SARS-CoV-2, secondary syphilis was confirmed by serological tests and skin biopsy, underlining that, even during a global pandemic, other common and important diseases should not be overlooked. The case also suggests thought on the ineffectiveness of distancing and social containment measures when dealing with sexually transmitted diseases. ©Copyright: the Author(s).

Entities:  

Keywords:  COVID-19; SARS-CoV-2; fragile populations; homeless population; screening

Year:  2020        PMID: 33437752      PMCID: PMC7789427          DOI: 10.4081/jphr.2020.2040

Source DB:  PubMed          Journal:  J Public Health Res        ISSN: 2279-9028


Introduction

On 11th March 2020, the World Health Organization (WHO) declared coronavirus 2019 disease (COVID-19) a pandemic.[1] In addition to the most common clinical features of COVID-19, which include fever, myalgia, cough, shortness of breath, ageusia, anosmia and conjunctival congestion,[2] skin symptoms can occur in up to 20.4% of patients.[3] A challenging aspect of such skin eruptions associated with COVID-19 is the great heterogeneity, that challenges a broad spectrum of differential diagnoses.[4] As the dermatologic signs may precede the respiratory symptoms or manifest themselves in the absence of any pulmonary manifestations, it is important to consider COVID-19 infection in case of any exanthematous eruptions to minimize the risk of spreading by pauci-symptomatic individuals in an endemic area. On the contrary, fear should not deter us from recognizing common disorders.

Case Report

In late March 2020, amidst the COVID-19 outbreak, a 58- year-old Caucasian man affected by insulin-treated type 2 diabetes referred to the Dermatology Clinic under the suspicion of SARSCoV- 2 infection for a generalized, mildly pruritic exanthematous rash associated with systemic symptoms of 2-week duration. He had been treated by the general practitioner with paracetamol and systemic steroids with some improvement, followed by relapse of symptoms and worsening of the skin eruption. He denied recent travels to the high-prevalence areas for SARS-CoV-2 infection. On physical examination, the patient presented with a widespread erythematous morbilliform rash, slightly papular and scaly at closer view on the trunk and radix of the limbs (Figures 1 and 2), more erythematous edematous on the face, with bilateral conjunctival erythema (Figure 2), associated with fever (37.9°C), cough, rhinitis, pharyngodynia, occipital headache, diffuse lymphadenopathy and symmetrical migratory arthritis. Isolated papules were present on the soles while palmar regions were spared. After inquiring the patient, he referred also a genital rash, which spontaneously resolved, two months earlier.
Figure 1.

Widespread erythematous morbilliform rash on the trunk and radix of limbs.

Figure 2.

Closer view of the slightly papular and scaly surface of the eruption on the abdomen. A more erythematous edematous component was present on the face, with bilateral conjunctival erythema.

Laboratory exams, including full blood count, coagulation tests, hepatic and renal function, HIV test were normal, except for a mild increase of ERS and C-reactive protein. Serum protein electrophoresis showed an increased gamma peak. Nasopharyngeal swab for SARS-CoV-2 was negative. The ophthalmologic consultation diagnosed a pan-uveitis. Histopathology of a skin biopsy showed a mild interface dermatitis, with superficial and deep dermal perivascular and periadnexal inflammatory infiltrate, whose multinucleated histiocytes formed several noncaseating granulomas in a background of lymphocytic infiltrate, rich in plasma cells (Figure 3). A positive Treponema pallidum hemagglutination (TPHA) test (>1:5120) as well as a rapid plasma reagin test (RPR 1: 64) confirmed the diagnosis of secondary syphilis. The patient was treated with penicillin G benzathine 2,400,000 UI intramuscularly weekly for 3 weeks with rapid improvement of systemic symptoms and complete resolution of the skin rash.
Figure 3.

Histopathology from skin biopsy: mild interface dermatitis, with superficial and deep dermal perivascular and periadnexal inflammatory infiltrate with several multinucleated histiocytes (Hematoxylin & Eosin stain, magnification 10X). On the right, particular of dermal noncaseating granulomas in a background of lymphocytic infiltrate, rich in plasma cells (inset). H&E, 20x; inset 40x.

The patient was tested negative for additional STD and at the trimestral follow up, RPR antibody titer had decreased (1:8), while TPHA test remained stable (1:5120).

Discussion

The reported prevalence of cutaneous signs associated with COVID-19 pandemic is variable, ranging from the 0.2% of a cohort of 1099 Chinese patients, to the 20.4% in a cross-sectional Italian study.[2,3] Exanthematous eruptions are considered the most common, although less specific COVID-19 related skin manifestations, reported in about 47% of cases.[4] The morphology is very polymorphic, and classification is limited by the subjectivity of the different reports’ description,[5,6] going from widespread erythema to urticarial, varicella-like/vesicular, purpuric, maculopapular, morbilliform and papulo-squamous presentation. In the American registry, 22% of the patients with laboratory-confirmed COVID-19 infection presented with a morbilliform rash, while another 9% with a papulo-squamous eruption, occurring mostly on the trunk and associated with mild itching.[7] It is therefore not surprising that the occurrence of a generalized morbilliform papular rash associated with cough and arthritis among the others,[8] during the most critical moment of the outbreak led to consider first a COVID-19 related manifestation. Of course, a closer observation recognized that all skin and systemic symptoms in our patient were typical of secondary syphilis, but one must also consider that admitting a person potentially affected with COVID-19 to hospital triggers a series of containment measures, and careful assessment should be performed.[9] More-over, social distancing and strict preventive measures during the lockdown are supposed to affect also the circulation of other infective diseases, such as syphilis. A decrease in STI diagnoses, particularly of early syphilis have been reported in Italy during the period of lockdown.[10,11] Our experience suggests not to let the guard down. Despite the global health emergency and the fear of non-recognizing COVID-19, other common diseases should not to be disregarded in everyday clinical practice. This is particularly true for a disease like secondary syphilis which can cause a wide range of symptoms, as the nickname of “great masquerader” points out, similar to actual COVID-19 manifestations.

Conclusion

Current pandemic is adsorbing most of the resources of our healthcare system, and specialty outpatients’ services, as well as Hospital Units not directly involved in critically ill COVID-19 patients’ risk to be overshadowed. A false sense of protection and social containment generated by lockdown measures can lead to underestimating sexually transmitted diseases circulation in the community. Especially syphilis diagnosis requires an expert eye, and a high level of suspicion, as it is characteristic of the dermatology on-field practice. Widespread erythematous morbilliform rash on the trunk and radix of limbs. Closer view of the slightly papular and scaly surface of the eruption on the abdomen. A more erythematous edematous component was present on the face, with bilateral conjunctival erythema. Histopathology from skin biopsy: mild interface dermatitis, with superficial and deep dermal perivascular and periadnexal inflammatory infiltrate with several multinucleated histiocytes (Hematoxylin & Eosin stain, magnification 10X). On the right, particular of dermal noncaseating granulomas in a background of lymphocytic infiltrate, rich in plasma cells (inset). H&E, 20x; inset 40x.
  11 in total

1.  Cutaneous manifestations in COVID-19: a first perspective.

Authors:  S Recalcati
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-05       Impact factor: 6.166

2.  The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries.

Authors:  Esther E Freeman; Devon E McMahon; Jules B Lipoff; Misha Rosenbach; Carrie Kovarik; Seemal R Desai; Joanna Harp; Junko Takeshita; Lars E French; Henry W Lim; Bruce H Thiers; George J Hruza; Lindy P Fox
Journal:  J Am Acad Dermatol       Date:  2020-07-02       Impact factor: 11.527

3.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

Review 4.  Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice.

Authors:  P Gisondi; S Piaserico; A Conti; L Naldi
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06       Impact factor: 9.228

Review 5.  Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue.

Authors:  A V Marzano; N Cassano; G Genovese; C Moltrasio; G A Vena
Journal:  Br J Dermatol       Date:  2020-07-05       Impact factor: 11.113

6.  Sexually transmitted infections during the COVID-19 outbreak: comparison of patients referring to the service of sexually transmitted diseases during the sanitary emergency with those referring during the common practice.

Authors:  L Sacchelli; F Viviani; G Orioni; P Rucci; S Rosa; A Lanzoni; A Patrizi; V Gaspari
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-29       Impact factor: 9.228

Review 7.  Dermatologic manifestations and complications of COVID-19.

Authors:  Michael Gottlieb; Brit Long
Journal:  Am J Emerg Med       Date:  2020-06-06       Impact factor: 2.469

8.  Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.

Authors:  C Galván Casas; A Català; G Carretero Hernández; P Rodríguez-Jiménez; D Fernández-Nieto; A Rodríguez-Villa Lario; I Navarro Fernández; R Ruiz-Villaverde; D Falkenhain-López; M Llamas Velasco; J García-Gavín; O Baniandrés; C González-Cruz; V Morillas-Lahuerta; X Cubiró; I Figueras Nart; G Selda-Enriquez; J Romaní; X Fustà-Novell; A Melian-Olivera; M Roncero Riesco; P Burgos-Blasco; J Sola Ortigosa; M Feito Rodriguez; I García-Doval
Journal:  Br J Dermatol       Date:  2020-06-10       Impact factor: 11.113

9.  WHO Declares COVID-19 a Pandemic.

Authors:  Domenico Cucinotta; Maurizio Vanelli
Journal:  Acta Biomed       Date:  2020-03-19

Review 10.  A Case of Reactive Arthritis Secondary to Coronavirus Disease 2019 Infection.

Authors:  Ian Yang Liew; Tze Minn Mak; Lin Cui; Shawn Vasoo; Xin Rong Lim
Journal:  J Clin Rheumatol       Date:  2020-09       Impact factor: 3.902

View more
  1 in total

1.  Concurrent coronavirus disease 2019 and primary syphilis in a young man: A rare case report.

Authors:  Yoshihiro Kitahara; Rie Nakamura; Mafumi Okimoto; Kei Miwata; Noriaki Ito; Toshiro Takafuta
Journal:  J Infect Chemother       Date:  2022-07-19       Impact factor: 2.065

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.